Bijlage 11

Dated April 2014

ATR!CURE EUROPE B.V.
ATRIOURE, INC.

and

Dr_

PHYSICIAN CONSULTING AGREEMENT

O

This Physician Consulting Agreement hereinaiter referred to as the “Agreement", is made on April 23th 2014, and will be effective as of May 1“ 2014;

BY AND BETWEEN:

(1) AtriCure Europe B.V. (the 'Company“). a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid) with its registered office at Schiphol Boulevard 127. 1118 BG Schiphol. the Netherlands; and

(2) AtriCure inc.. 6033 Schumacher Park Drive. West Chester. Ohio
both referred to )ointiy and severally. as “AtriCure';

(3) the 'Consultant', whose principal piece of business is at 'Academisch Medisch Centrum Amsterdam', Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;

the Company and the Consultant hereinafter jointly referred to as the 'Partles' and individually as
the “Party‘;

WHEREAS:

(A) the Company owns and/or has rights to certain proprietary technology in cardiac surgery and other fields and develops, manufactures and sells various medical devices for use in surgical procedures;

(B) the Consultant has significant medical and scientific expertise and knowledge in the field of cardiac surgery and/or electrophysiology.

(C) the Company desires to utilize the services of the Consultant and the Consultant wishes to provide such services to the Company all in accordance with the terms and conditions set out below, and

(D) the Consultant acknowledges that, for the purpose of providing such services to the Company, he will have confidential information of AtriCure as defined below al his disposal, which he will treat confidentially all in accordance with the terms and conditions set out
below.

NOW THEREFORE:
in consideration of the mutual obligations specified in this Agreement, the Parties agree as follows.

1 Scope of Services to be Provided by Consultant

1.1 The Consultant shall, as requested by the Company, provide services as mentioned under molta! (C) above, to or on behalf of the Company pursuant to this Agreement (as defined below) (overeenkomst van opdracht as defined in Section 7:400 of the Dutch Civil Code). Such services may include, but not necessarily be limited to:

1.1.1 training and preceptor ship services to be provided to physicians for the use(s) of products of the Company;

1.1.2 feedback, advice and consultation pertaining to the Company product research, development, and market positioning;

1.1.3 feedback, advice and consultation on clinical programs and projects identified by the Company; and1.1.4

such other services for which the Consultant is qualified.

1.2 The services referred to in Clause 1.1 will be defined as the "Services” hereinafter.

1.3 At the request ofthe Company. the Consultant will attend certain scientific advisory
meetings sponsored by the Company and provide feedback on the topics presented.
including but not limited to:

1 .3.1
1 ‚3.2

1 .3.3

1 .3A
1 ‚3.5
1 ‚3.8

1 .3.1

issues relating to the Company's current products and their use;
evaluation of concepts and/or prototype devices;

professional experience with medical and surgical treatment methods
(provided such disclosure does not breach any other existing confidentiality
or non-disclosure agreement or a corresponding obligation towards third
parties);

clinical study design;
patient selection, management and compliance;
design and accuracy of marketing materials; and

clinical outcomes.

2 Schedule of and Availability to Provide Services

The Company and the Consultant agree to use their best efforts to mutually agree en the
schedule pursuant to which the Consultant shall provide the Services. The Services shall
be provided at the offices of the Company or at another mutually agreed upon location.
The amount of time required to be devoted by the Consultant to the provision of Services
as well as the specific programs and projects on which the Consultant will be requested to
provide Services. will be agreed to by the Parties in writing and attached to this Agreement
from time to time as amended. The Consultant agrees to use best efforts to maintain his
availability to provide such Services for or on behalf of the Company at reasonable times
and at mutually agreed upon times and places.

3 Compensation

3.1 In consideration for the provision of the Services. the Company shall pay to the
Consultant a compensation In the following amounts:

3.1.1

3.1.3

3.1 .‘

two thousand two hundred fifty euros (€ 2.250) per day for training
physicians In the Company’s technique and technology outside his hospital;

one thousand five hundred euros (€ 1.500) per event for Consultant travel
time in the European Union or weekends in North America;

one hundred fifty euros (€ 150) per hour. or one thousand two hundred fifty
euros (€ 1.250) per event for presentation. conferences. seminar and
ground rounds. or a pro rata amount for any fraction of a day during which
these services are provided to the Company; and

one hundred fifty euros (€ 150) per hour to provide feedback on new
products and/or technologies. or a pro rata amount for any fraction of a day
during which the Services are provided to the Company.

 

3.2

3.3

3.4

3.5

3.6

3.7

3.8

For the purpose of this Clause 3, a day shall be defined as a minimum of eight (8)
hours.

The total compensation per year shall not exceed fifty thousand euros (€ 50.000)
without written consent from all Parties. The maximum daily payment shall not
exceed the event allowance as specified in Clauses 3.1.1 —- 3.1.4.

Compensation for the provision of the Services by the Consultant shall be
conditioned an end subject to receipt and approval by the Company of a record of
the time expanded in the provision of Services. and a description of the Services
provided ('Time Record'). prepared and signed by the Consultant and forwarded to
the Company. The Time Record shall be in the form attached to this Agreement as

&flii'âíâá-

The Consultant understands and agrees that until the Consultant provides to the
reasonable satisfaction of the Company complete and accurate Tune Records. the
Company is not obligated to and will not compensate the Consultant under this
Agreement. Approved invoices will be paid within thirty (30) days following approval
by the Company of the relevant Time Records.

The Company shall reimburse the Consultant for all reasonable expenses incurred
by the Consultant In connection with the provision of the Services. provided that any
expense exceeding one hundred euros (€ 100) shall be approved in advance by the
Company. Prior to payment of any reimbursement for expenses. the Consultant
agrees to itemize and submit to the Company recelpts for each expense. Including
travel. Approved invoices will be paid within thirty (30) days following approval
thereof by the Company.

In the case that the Consultant is scheduled to provide any of the Services et en
event and that event is cancelled less than forty-eight (48) hours. but more than
twenty-four (24) hours. prior to that event. the Company will compensate the
Consultant for four (4) hours of service based on the hourly rates identified in
Section 3.1.4. if the cancellation occurs less than twenty-four (24) hours prior to the
event. the Company will compensate the Consultant for eight (8) hours of service.

The Time Record is to be received by AtriCure within ninety (90) days from the date
the Services were provided. lithe Time Record is received by AtriCure stier ninety
(90) days from the date the Services were provided, it is up to the discretion of
AtriCure to pay or not to pay the Consultant for those Services.

Representations and Warranties

4.1

4.2

The Company and the Consultant each represent that the compensation described
in this Agreement is Intended to be and. In the good faith of the Parties. represents
the fair market value of the Services provided, and is expresst not conditioned in
any way en the volume or value of any business (i) between the Company and any
purchaser. or (ii) resulting. dimctly or indirectly, from any of the Services provided by
the Consultant under this Agmement.

No amount paid under this Agreement is intended to be. nor shall it be consirued as.
an offer or payment made in exchange for any explicit or implicit agreement to
purchase. prescribe. or mcommend any of the Company's product or service.

 

4.3

The Consultant represents and warrants to the Company that:

4.3.1

4.3.2

4.3.3

4.3.4

4.3.5

4.3.6

4.3.7

he has an unrestricted license to practice medicine in the Netherlands
evidenced through the documentation attached as Sc@uie 4.3.1 to this
Agreement and this license to practice medicine in the Netherlands has not
been revoked or limited in any way;

he has not been excluded. deleted from the Individual Healthcare
Professions Register (Beroepen Individuele Gezondheidszorg-raglsfer). nor
to the best of his knowledge is be the subject of any pending (legal)
proceedings which may result In hls debannent under the individual
Healthcare Professions Act (Wet op de Beroepen in de Individuele
Gezondheidszorg). by a disciplinary tribunal of the Central information Unit
on Healthcare Professions (Centraal Informatiepunt Beroepen
Gezondheidszorg) or by the Healthcare Inspectorate (of the Public Health
Supervisory Service) (Inspectie voor de Gezondheidszorg) and that he has
the ability to practice medicine and complies with the EU Medle Device
Directive (Richtlijn betreffende medische hulpmiddelen) (93/42/EEG);

he has no obligations to or relationships with other parties. including
without limitation any employer of the Consultant. that would:

(i) present a conflict with carrying out the duties under this Agreement;

( !) prevent the Consultant from carrying out the duties under this
Agreement; or

(iii) present a significant potential for disclosure of information to the
Company that is not publicly known and that the Consultant is
obiigated to a third party to keep confidential;

he shall disclose to any employer of his that he is to enter into a paid
consulting agreement with the Company and that he has received the
employer's written consent;

he has disclosed to the Company any arrangements he has as of the
Effective Date. with any company or entity that manufactures. markets or
sells or is researching or developing any drug. biological. or device for the
medical or surgical treatment of atriai fibriiiation or the exclusion or
treatment of the left atriai appendage ('Other Companies') evldenced
through the documentation attached as Schäule 4.3.5 to this Agreement;

he will advise the Company in writing of any additional or intended
anangement with Other Companies prior to the effective date of any such
arrangement. The Parties recognize and agree that while the Consultant
may enter into arrangements with Other Companies. the Company may. in
its soie discretion. deem eny such arrangement to conflict with the interests
of the Company. and tanninate this Agreement effective upon five (5) days
prior written notice to the Consultant. Vioiation of this provision shall be
deemed to be a material breach;

he shall comply with all applicable Dutch and EU laws and regulations
including but not limited to. the Public Health Act (Gezondheidswet). the
individual Healthcare Professions Act (Wet op de Beroepen In de

 

/\

4.4

Individuele Gezondheidszorg) and regulations of the Healthcare
lnspectorate (of the Public Health Supervisory Service) (Inspectie voor de
Gezondheidszorg): and

4.3.8 he shall have in effect at all times during this Agreement, all licenses,
permits and authodzratlons for all govemmental agencies to the extent the
same are necessary to the perfomance of the Services and will verify al]
are in place before accepting any assignment under this Agreement, and
shall not accept any assignment under this Agreement for which he does
not hold al! necessary licenses/pennlts/govemment authorizations.

During the Term of this Agreement (as defined below) and for a period of six (6)
months therealter. if the Consultant uses. recommends. or comments upon the
attributes of any Company product or service In connection with the treatment of a
patient, a scientific or educational presentation or publication. a media interview, or
any other third—party communication or interaction. the Consultant shall disclose that
he is, or has been, a paid consultant of the Company and any and all other of his
financial relationships with the Company.

Indemnification

5.1

5.2

The Consultant agrees to indemnlfy and hold harmless the Company for any claims
or actions or damages or expenses (including reasonable attomey‘s fees) for which
the Company is liable that arlse from or are related to:

5.1.1 the breach by the Consultant of this Agreement; or

5.1.2 any negligence or wliful misoonduct by the Consultant in connection with
the Services, including any breach. negligence or wiiful misconduct
regarding the Consultants representations. warranties and obligations
under Clause 4 to this Agreement.

The Company agrees lo indemnify and hold harmless the Consultant for any claims,
actions, damages or expenses (Including reasonable attomey's fees) for which the
Consultant is liable that arise from or are related to:

5.2.1 the breach by the Company of this Agreement; or

5.2.2 any negligence or wilful misconduct by the Company in connection with its
representations and obligations to the Consultant.

Liaison at the Company

The Company will from time to time, and upon notice to the Consultant, designate an
employee of the Company to serve as liaison behrveen the Company and the Consultant in
connection with the provision of Services by the Consultant, including issues concerning

scope of work. scheduling and relmbursernent of expenses. Such liaison mai chaîe at

Comianis discretion uî notice to the Consultant. The initial liaison shall be

 

7 Confidential Information

7.1

7.2

7.3

During the term and in furtherance of the provision of Services. the Consultant may
receive information that AtriCure regards as confidential or proprietary. including but
not limited to information about know-how. processes and practices. business.
scientific or technlml information Including but not limited to research. product plans
and development. services. customer lists. pricing. markets. schwere,
developments, Inventions. processes, formulas. technology. designs. drawings.
engineering. hardware configuration information. marketing or financial information
(the "Confidential information").

Confidential Information does not include information that is:
7.2.1 lawfully known by the Consultant at the time of disclosure;

7.2.2 publicly known at the time of disclosure or subsequently becomes publicly
known through no fault of the Consultant;

7.2.3 acquired by the Consultant from a third party that is not under an obligation
of confidentiality regarding disclosure or use of such information;

7.2.4 is required by law to be disclosed by the Consultant;

7.2.5 is disciosed by the Consultant with AtriCure's prior written approval (which
approval AtriCure may withhold or condition in its sole and absolute
discretion); or

7.2.6 ls independently developed by the Consultant without use of Confidential
information of AtriCure.

In the event that Confidential information shall be subject to disclosure pursuant to a
court order or otherwise under law. the Consultant shall give AtriCure prompt written
notice of such requirement prior to disciosing any Confidential information and shall
take reasonable steps to allow AtriCure sufficient time to contest or limit any such
request or seek a protective order or other appropriate remedy or. in its sole
discretion. waive compliance with the terms of this Agreement. provided, however. In
the event that no such protective order or other remedy is obtained. or thet AtriCure
does not waive compliance with the terms of this Agreement. the Consultant will
furnish only that portion of the Confidential Information Which his counsel advises is
legally required and will exercise I   reasonable efforts to obtain reliable assurance
that confidential treatment will be accorded to the extent possible.

8 Ownership Confidential information

8.1

8.2

All materials provided by AtriCure under this Agreement shall remain the property of
AtriCure. The Consultant shall immediately return to AtriCure any Confidential
Information. together with all related records. notes and other written. printed. or
tangible materials in its possession pertaining to Confidential infomation. lfAtriCure
so requests in writing and in any event at terrnination of this Agreement. The
returned materials shall be accompanied by an executed certificate of the
Consultant certifylng compliance with this Clause 8.1.

Nothing contained in this Agreement shall be construed as transferring any
proprietary. trademark or patent and any other rights of AtriCure In the future are
expressly reserved to belong exclusively to AtriCure.

 

8.3

AtriCure is not obligated to furnish Confidential Information to the Consultant and
does not make any representation or warranty as to the accuracy or completeness
of the Confidential Information. AtriCure shall have no liability to the Consultant
resulting from the use of the Confidential Information by the Consultant.

Obiigations of Consultant

9.1

9.2

9.3

9.4

The Consultant agrees he will at all times keep and maintain the Confidential
Information. and any Confidential Information developed by the Consultant in
performing the Services. In the strictest confidence for the soie and exclusive benefit
of AtriCure and shall not permit its disclosure to third parties, except as otherwise
contemplated under this Agreement. Any other use of Confidential Information shall
be consldered extraneous in the absence of prior written approval.

The Consultant shall carefully restrict access to Confidential Information to
employees. contractors and third parties (collectiver referred to as
'Representatives"). except as is reasonably required for the Consultant to meet its
obligations to AtriCure and to perform under this Agreement. The Consultant shall
instruct the Representatives who have access to the Confidential Information of the
necessity to maintain the confidentiality of the Confidential Infonation and shall
procure that the disclosure or use of the Confidential Information other than as
permitted in this Agreement is prevented. In the event that the Consuitant shall
secure similar agreements to this Agreement from such third party contractors on
terms no less restrictive than contained in this Agreement, it shall be stated in these
agreements that the Confidential information as described herein belongs
exclusively to AtriCure.

The Consultant shall not, without prior written approval of AtriCure, use extraneoust
for the Consultants own benefit. prematurer publish. transmit or distribute or
othenwise extraneously disclose to any third parties. or permit the use by any third
parties for their benefit orto the detriment of AtriCure. any Confidential Information.

The Consultant represents that he has no agreements or obligations to any third
parties in conflict with his obligations to AtriCure contemplated herein and that if any
present obligation to another party is deemed by It to conflict with any work or
undertaking for AtriCure pursuant to this Agreement. the Consultant shall promptly
notify AtriCure of that facts so that appropriate measures may be taken to avoid
such conflict.

The Consultant acknowledges that AtriCure has received and in the future will
receive from third parties their confidential or proprietary information subject to a
duty on AtriCure‘s part to maintain the confidentiality of such Information and to use
it only for certain limited purposes. The Consultant agrees to hold al! such
confidential or proprietary infomation in the strictest confidence. in accordance with
AtriCure's agreement with the third party. and not to disclose it or use it except as
approved in writing by AtriCure.

 

10 Period of confidentiality

11

10.1 The non-disclosure provisions of this Agreement shall survive the cancellation
(beëindiging). termination (opzegging). amendment pursuant to Section 6: 230 of
Book 6 Dutch Civil Code and rescission (ontbinding) of this Agreement and the
Consultants duty to hold the Confidential Information in confidence shall remain in
effect until the earlier of ( ) five (5) years following the cancellation (beëindiging),
terrnination (opzegging) and rescisslon (ontbinding) of this Agreement. or (ii) after
receipt of a written notice from AtriCure to the Consultant, releasing the Consultant
from the obligations as stated in Clauses 7 to 9.

10.2 The opportunity to receive Confidential information under this Agreement may be
cancelled at any time in writing by AtriCure. Such cancellation shall not affect any
obligation imposed by this Agreement with respect to Confidential information
received prior to such cancellation.

insider information

11.1 The Consultant understands. acknowledges and agrees that:

11.1.1 as a result of his relationship with the Company. he may periodicaliy
possess Confidential information that is considered to be “material" and
'non-public' information under applicable securities laws;

11.1.2 the Company has adopted en insider trading policy that contains certain
black-out periods for holders of material non-public information. That black—
out period begins en the first day of the last two weeks of a fiscal quarter
and ends forty-eight (48) hours following the release of earnings;

11.1.3 he shall not buy, sell, pledge or otherwise trade for himself. a third person
or a company, in the Companis stock or options, or enter into any
transaction having the same economic effect. while in possession of
material non-public Confidential information;

1i.1.4 he shall not buy, sell, pledge or otherwise trade for himself, a third person
or a company. in the Company‘s stock or options without obtaining prior
pre-approval from AtriCure, Inc.'s Chief Executive Officer or Chief Financial
Officer,

11.1.5 he shall not disclose such material non-public Confidential Information to
any third party until such Confidential Information othemise becomes
publicly avaliable; and

11.1 .e he shall not - without iimiting any confidentiality obligations included in the
Clauses 7. 8 and 9- discuss any information concerning the Company
obtained by the Consultant in the course of perfonnlng the Services with
any financial, securities or industry analyst or with the media without the
written consent of the Company.

11.2 For purposes of this Clause 11 the term 'material' means Information that a

reasonable investor would consider important in making an Informed investment
decision; and the term "non-public" means not made generally known by press
release, conference cali open to the public, or in a filing with the Securities and
Exchange Commission.

 

12

13

14

Intellectual Property

For the consideration set out in this Agreement. the Consultant transfers and assigns to the
Company al! his right. titie and interest in (i) al! written material or other works that raad en
any current AtriCure patents. (ii) al! patentable and unpatentable inventions. discoveries or
ideas. that are made, conceived of er written by the Consultant in the performance of his
obligations under this Agreement, and (iii) any intellectual property rights that are
conceived or developed by AtriCure sponsored labs er activities (together 'Intellectual
Property”). The Consultant will promptly disclose Intellectual Property to the Company in
writing. The Consultant warrants to claim all inventions of his employees made during the
term of this Agreement independently, in due time and according to the legal requirements.
Upon the Company's request and at the Company's expense. the Consultant will assist the
Company or anyone it designates in filing copyright er patent applications worldwide
relating te intellectual Property. The Consultant will execute al! papers and take all other
actions necessary and advisabie‚ in the Company's opinion. to file and prosecute such
applications.

Off-Label Marketing and Promotion

13.1 Consultant acknowledges that AtriCure as a device manufacturer may not market
or promote its products for uses that have not been approved or cleared by the
applicable regulatory authority er authorities. This means that Consultant when
acting en behalf of Company may not make any claims regarding the safety or
effectiveness of any Company product for a use that has not been cleared or
approved by the applicable regulatory authority or authorities.

Breach of Contract

14.1 The Consultant accepts that due to the unique nature of the Confidential information
any breach of each of the Clauses 7 te 12 of this Agreement could cause ineparable
injury and damage to AtriCure. Accordingly‚ in case of any breach of each of the
Clauses 7 to 12 of this Agreement the Consultant shall be obligated to pay AtriCure
a penalty in the amount of two hundred fifty thousand euros (€250,000). without
prejudice to the AtriCure's right to claim the actual damages if they exceed the
amount of two hundred fifty thousand euros (6250000) and the Consultant shall
continue to remain liable in respect of specific perfomance of the obligations set
forth in this Agreement.

14.2 Any breach as mentioned in Clause 13.1 by the Consultant shall not result in the
cancellation. termination or rescission of this Agreement or any other agreement
and/or any obligation ofthe Consultant there under unless declared so by AtriCure in
writing.

14.3 The Consultant acknowledges that remedies at law may be inadequate to protect
AtriCure against any actual or threatened breach of each of the Clauses 7 te 12 of
this Agreement by the Consultant or its Representatives. and. without prejudice to
any other rights and remedies otherwise available to AtriCure. the Consultant agrees
that AtriCure (and/or lts relevant affiliates or subsidiaries) shall be entitled to
injunctive relief in a court of competent jurisdiction and the Consultant shall
reimburse AtriCure for any costs. claims. demands. or iiabiiities arising directly er
indirectly out of a breach. Nothing contained in this Agreement shall be construed as

 

prohibiting a Party or any of its affiliates or subsidiaries from pursuing any other
remedies available to it for a breach or threatened breach.

15 Term and Renewal

16

17

18

15.1

1 5.2

This Agreement will be in effect for a period of two (2) years commendng as of the
Effective Date (the “'l'erm").

This Agreement may be renewed for additional one (1) year term upon a mutual
written agreement signed by both Parties not less than thirty (30) days prior to the
end of the current term.

Termination

1 6.1

1 6.2

Upon a material breach of the Agreement by one Party, the non—breaching Party
may terminate this Agreement. such tennination to be effective upon receipt of
notice to the breaching Party. provided however. that at the soie option of the non-
breaching Party. the breaching Party shall be given ten (10) days to cure such
breach to the satisfaction of the non-breaching Party.

This Agreement may be terminated at any time upon thirty (30) calendar days
written notification by either Party.

Survival of Terms

Ciauses 4, 7 to 9. 11 and 12 shall survive the tennination of this Agreement for any reason
whatsoever.

Miscellaneous

18.1

18.2

18.3

18.4

18.5

This Agreement constitutes the entire understanding between the Company and the
Consultant with respect to the subject matter recited herein and supersedes all prior
agreements. obligations and undertakings. written or oral, that may have existed at
the time of execution of this Agreement.

This Agreement may be amended or modified only in a written document signed by
both Parties.

This Agreement shall be binding upon and inure to the benefit of the Parties and
their successors and essigns provided that no Party may assign its respective rights
and obligations under this Agreement without the prior written consent of the other

Party.

None of the provisions of this Agreement are intended to create. nor wii! they be
deemed to create. any relationship between the Parties other than that of
independent Parties contracting with each other solely for the purposes of eiiecting
the provisions of this Agreement and any other agreements between the Parties
evidencing their business relationship.

This Agreement will be governed by the laws of the Netheriands. Any dispute arising
under or in relation to this Agreement shall to the exclusion of any other Court. be
brought before the competent Court of The Hague. the Netherlands.

 

10

19

18.6

18.7

18.8

No change. walver or discharge of any liability or obligation hereunder on any one or
more occasions nor any failure to exercise any right provided in this Agreement shall
be deemed a waiver of performance of any continuing or other obligations. or shall
prohibit enforcement of any obligation, on any other occasion.

In the event that any provision of this Agreement is held by a court of competent
jurisdiction to be invalid or unenforceable, the remainder of the provisions of this
Agreement will remain in full force and effect.

This Agreement may be executed in one or more counterparts. and by the different
Parties hereto in separate counterparls. each of which when executed shall be
deemed to be en original but al! of which taken together shall constitute one and the
same agreement.

Notifications

19.1

19.2

Any notification required in this Agreement shall be made in writing to the individual
who signed the Agreement or the person currently sewing in that representetlve's
position with the other Party.

Any notification required in this Agreement may be provided to the other Party by
registered mall or delivery by a qualified courier both with return receipt requested.

[signatum page follows]

 

11

SIGNED by

ll lllllf of lriCul Emil B.V.

 

 

SIG

 

\W—J _r—’“—v—J“W—’_f—'

 

12

Atri€ure

SCHEDULE 3.4 CONSULTANT TIME RECORD

 

 

Fax te:
Attention:
e u
Consultant: Dr_
Date Description of Consulting Services Name(s) of Key Location of Key Hours
Performed Participant(s) Participent(s)

 

 

 

 

 

 

 

 

 

This record is a complete and accurate description of the work   performed on behalf of AtriCure
Europe B.V. for which ! request oompensetlon.

 

 

Consultant Signature Date

Address:

 

Postal code. City. Country:

 

Payment detail
Bank neme:

 

Bank account number:

 

IBAN number bank account:

 

BIC number:

 

13

 

Atrì€ure

SCHEDULE 4.3.1 EVIDENCE OF LICENSE

 

14

Atrì€ure

SCHEDULE 4.3.5 EVIDENCE OF OTHER COMPANIES

 

15